Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

360
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
360
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.2K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.2K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

488
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
488
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

521
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
521

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectory of liver-related events following incident cardiovascular disease in MASLD: A 15-year population-based cohort study.

Metabolism: clinical and experimental·2026
Same author

Delphi survey to explore core curriculum for training the next-generation of hepatologists<sup>☆</sup>.

JHEP reports : innovation in hepatology·2026
Same author

Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026
Same author

MASLD prevalence, incidence and global aspects.

Diabetologia·2026
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Apr 13, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K

NAFLD: a multisystem disease.

Christopher D Byrne1, Giovanni Targher2

  • 1Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK; Southampton National Institute for Health Research, Biomedical Research Centre, University Hospital Southampton, UK.

Journal of Hepatology
|April 29, 2015
PubMed
Summary
This summary is machine-generated.

Non-alcoholic fatty liver disease (NAFLD) is a common liver condition that affects multiple organs. Emerging evidence shows NAFLD significantly increases the risk of type 2 diabetes, cardiovascular disease, and chronic kidney disease.

Keywords:
Cardiac arrhythmiasCardiac diseaseCardiovascular diseaseChronic kidney diseaseHepatocellular carcinomaInsulin resistanceNon-alcoholic fatty liver diseaseType 2 diabetes

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K
Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.7K

Related Experiment Videos

Last Updated: Apr 13, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K
Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.7K

Area of Science:

  • Hepatology and Internal Medicine

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in Western nations.
  • NAFLD is projected to be the leading cause for liver transplantation by 2030.
  • NAFLD's impact extends beyond the liver, affecting multiple organ systems.

Purpose of the Study:

  • To review the clinical evidence supporting NAFLD as a multisystem disease.
  • To discuss factors contributing to NAFLD progression and its links to other chronic conditions.
  • To explore the association of NAFLD with type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD).

Main Methods:

  • A narrative review of existing clinical evidence.
  • Literature search of PubMed using keywords: "non-alcoholic fatty liver disease" or "fatty liver" combined with "diabetes", "cardiovascular (or cardiac) disease", "cardiovascular mortality", or "chronic kidney disease".
  • Inclusion of articles published between 1990 and 2014 in English.

Main Results:

  • NAFLD is increasingly recognized as a multisystem disease with significant extra-hepatic manifestations.
  • NAFLD is strongly associated with increased risks of T2DM, CVD, cardiac diseases, and CKD.
  • Cardiovascular disease accounts for the majority of deaths in patients with NAFLD, despite liver-related complications.

Conclusions:

  • NAFLD is a complex condition with systemic implications, extending beyond liver pathology.
  • Understanding the links between NAFLD and other chronic diseases is crucial for patient management.
  • Further research is needed to elucidate the mechanisms driving these extra-hepatic manifestations.